post-template-default,single,single-post,postid-14200,single-format-standard,strata-core-1.1,strata-theme-ver-3.3,ajax_fade,page_not_loaded,mob-menu-slideout-over,wpb-js-composer js-comp-ver-6.4.1,vc_responsive


Abu Dhabi launches RWE study on AstraZeneca’s antibody combination, Evusheld

09:33 30 August in News

The Department of Health – Abu Dhabi (DoH) has announced launching a Real-World Evidence Study to offer critical real-world data on the safety and effectiveness of AstraZeneca’s long-acting antibody combination, Evusheld. Evusheld was launched last March in UAE to protect immunocompromised patients against COVID-19. It has been shown to significantly reduce the risk of severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic infections. It is though that approximately 2% of the global population have compromised immune systems, making them unresponsive or insufficiently responsive to the COVID-19 vaccine. Evusheld has already received emergency use authorisation in each of UAE, Saudi Arabia, Bahrain, Qatar and Egypt and is the only antibody therapy to receive emergency use authorisation in the US for pre-exposure prevention of COVID-19. The EVOLVE Study, is expected to continue until the end of 2023 with up to 1,000 participants, in a collaboration between AstraZeneca and Sheikh Khalifa Medical City (SKMC) hospital in Abu Dhabi, under the supervision of DoH.

#PhoenixCR #COVID19 #ClinicalResearch #MENA #MiddleEast #CRO #AbuDhabi #UAE